OBJECTIVE: To evaluate the clinical efficacy and safety of a transcatheter arterial embolization (TAE) with N-butyl cyanoacrylate (NBCA) for the treatment of arterial esophageal bleeding. MATERIALS AND METHODS: Between August 2000 and April 2008, five patients diagnosed with arterial esophageal bleeding by conventional angiography, CT-angiography or endoscopy, underwent a TAE with NBCA. We mixed NBCA with iodized oil at ratios of 1:1 to 1:4 to supply radiopacity and achieve a proper polymerization time. After embolization, we evaluated the angiographic and clinical success, recurrent bleeding, and procedure-related complications. RESULTS: The bleeding esophageal artery directly originated from the aorta in four patients and from the left inferior phrenic artery in one patient. Although four patients had an underlying coagulopathy at the time of the TAE, angiographic and clinical success was achieved in all five patients. In addition, no procedure-related complications such as esophageal infarction were observed during this study. CONCLUSION: NBCA can be an effective and feasible embolic agent in patients with active arterial esophageal bleeding, even with pre-existing coagulopathy.
OBJECTIVE: To evaluate the clinical efficacy and safety of a transcatheter arterial embolization (TAE) with N-butyl cyanoacrylate (NBCA) for the treatment of arterial esophageal bleeding. MATERIALS AND METHODS: Between August 2000 and April 2008, five patients diagnosed with arterial esophageal bleeding by conventional angiography, CT-angiography or endoscopy, underwent a TAE with NBCA. We mixed NBCA with iodized oil at ratios of 1:1 to 1:4 to supply radiopacity and achieve a proper polymerization time. After embolization, we evaluated the angiographic and clinical success, recurrent bleeding, and procedure-related complications. RESULTS: The bleeding esophageal artery directly originated from the aorta in four patients and from the left inferior phrenic artery in one patient. Although four patients had an underlying coagulopathy at the time of the TAE, angiographic and clinical success was achieved in all five patients. In addition, no procedure-related complications such as esophageal infarction were observed during this study. CONCLUSION:NBCA can be an effective and feasible embolic agent in patients with active arterial esophageal bleeding, even with pre-existing coagulopathy.
Authors: M P Schenker; R Duszak; M C Soulen; K P Smith; R A Baum; C Cope; D B Freiman; D A Roberts; R D Shlansky-Goldberg Journal: J Vasc Interv Radiol Date: 2001-11 Impact factor: 3.464
Authors: William T Kuo; David E Lee; Wael E A Saad; Nikhil Patel; Lawrence G Sahler; David L Waldman Journal: J Vasc Interv Radiol Date: 2003-12 Impact factor: 3.464
Authors: Victoria Gómez; Joshua A Propst; Dawn L Francis; Juan M Canabal; Pablo Moreno Franco Journal: Dig Dis Sci Date: 2014-05-07 Impact factor: 3.199